<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03017950</url>
  </required_header>
  <id_info>
    <org_study_id>170DDI16017</org_study_id>
    <nct_id>NCT03017950</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Drug-drug Interaction of CKD-330 and D086</brief_title>
  <official_title>Phase I Clinical Trial to Evaluate the Pharmacokinetic Drug-drug Interaction of CKD-330 and D086 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is examining and comparing the pharmacokinetic drug interaction and
      safety of both single administration and combination administration of CKD-330 and D086 to
      healthy male subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, randomized, multiple-dose, 2-sequence, 2-period, 2-treatment, crossover study

      Part1: Examining how D086 affects pharmacokinetics of CKD-330. Part2: Examining how CKD-330
      affects pharmacokinetics of D086.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss of Candesartan and Amlodipine</measure>
    <time_frame>Day6, Day7, Day8, Day9, Day22, Day27, Day28, Day29 and Day30</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCτ,ss of atorvastatin and 2-hydroxy atorvastatin</measure>
    <time_frame>Day6, Day7, Day8, Day9, Day22, Day27, Day28, Day29 and Day30</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Hypertension</condition>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Part1 (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Subjects: 10
Number of days for Period 1: 8
Number of days for Period 2: 8
Number of days for wash-out between period 1 and period 2: 14
IPs for Period 1: CKD-330
IPs for Period 2: CKD-330 + D086</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part1 (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Subjects: 10
Number of days for Period 1: 8
Number of days for Period 2: 8
Number of days for wash-out between period 1 and period 2: 14
IPs for Period 1: CKD-330 + D086
IPs for Period 2: CKD-330</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2 (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Subjects: 30
Number of days for Period 1: 8
Number of days for Period 2: 8
Number of days for wash-out between period 1 and period 2: 14
IPs for Period 1: D086
IPs for Period 2: CKD-330 + D086</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part2 (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Number of Subjects: 30
Number of days for Period 1: 8
Number of days for Period 2: 8
Number of days for wash-out between period 1 and period 2: 14
IPs for Period 1: CKD-330 + D086
IPs for Period 2: D086</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-330</intervention_name>
    <arm_group_label>Part1 (A)</arm_group_label>
    <arm_group_label>Part1 (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D086</intervention_name>
    <arm_group_label>Part2 (A)</arm_group_label>
    <arm_group_label>Part2 (B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CKD-330 + D086</intervention_name>
    <arm_group_label>Part1 (A)</arm_group_label>
    <arm_group_label>Part1 (B)</arm_group_label>
    <arm_group_label>Part2 (A)</arm_group_label>
    <arm_group_label>Part2 (B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult males age of between 19 - 45 on the day of screening.

          2. Body mass index(BMI) between 18.0 - 29.0 kg/m^2 and weight ≥ 55kg (Body mass index
             (BMI) = weight (kg) / height (m)^2)

          3. Subjects in good health as determined by physical exams and medical examinations. No
             congenital or chronic diseases and no abnormal signs determined by medical
             examinations.

          4. Not abnormal or not clinically significant lab values.

          5. Subjects who signed informed consent form with good understandings after explanations
             by investigators.

        Exclusion Criteria:

          1. No history or presence of clinically significant cardiac, respiratory, neurological,
             endocrine, metal and renal diseases and liver and kidney diseases.

          2. Subjects showing angioedema as an adverse reaction to ACE inhibitors

          3. Primary Hyperaldosteronism

          4. History or family history of myopathy

          5. Subjects with mental diseases or drug addiction

          6. Allergic reactions to candesartan or amlodipine or atorvastatin

          7. Genetic problems in galactose intolerance, Lapp lactose deficiency, or
             glucose-galactose malabsorption.

          8. Hypotension(SBP ≤100mmHg or DBP≤55mnHg) or hypertension ( SNP ≥ 150mmHg, DBP ≥95mmHg)
             on the day of screening

          9. Subjects who experienced gastrointestinal diseases or surgeries which can affect
             absorption of Investigational product

         10. Subjects with abnormal lab values at least one below

             (AST or ALT&gt;2 fold of upper normal limit, Total bilirubin&gt;2 fold of upper normal
             limit, CPK&gt;2 fold of upper normal limit, K &lt;3.5mEq/L or &gt;5.5mEq/L, Estimated
             Glomerular filtration rate&lt;60mL/min/1.73m2 by Modification)

         11. Continuous drinking (over 21 units/week, 1 unit= 10g=12.5mL of pure alcohol), heavy
             smoker(&gt; 10 cigarettes per day) and unable to stop drinking during clinical trials

         12. Subjects who previously participated in other clinical trials within 90 days

         13. Subjects who donated whole blood within 60 days or donated component blood within 30
             days or received blood transfusion within 30 days

         14. Subjects who were administered below medications within 30 days (cyclosporin,
             erythromycin, clarithromycin, lopinavir, ritonavir, itraconazole, ketoconazole,
             rifampicin, barbiturate : theses medicines could affect absorption, metabolism,
             distribution and excretion of candesartan,amlodipine and atorvastatin)

         15. Subjects who took any prescribed medications or oriental medicines within 14 days, or
             took any pharmacy medicines within 7 days.

         16. Subjects who have taken any diets affecting absorption, metabolism, distribution and
             excretion of investigational products (especially grapefruit juice).

         17. Subjects who are in conditions impossible participating in the clinical trials
             following other laboratory tests.

         18. Unable to use contraceptions.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2017</study_first_posted>
  <last_update_submitted>July 19, 2017</last_update_submitted>
  <last_update_submitted_qc>July 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

